Simon J. Harrison - Concepedia

Author

Simon J. Harrison

Also Known As

S Harrison, S J Harrison, S. Harrison, S. J. Harrison, S.J. Harrison, Sarah Pendlebury, Simon Harrison, Simon J Harrison, Simon J. Harrison, Simon James Harrison

476

Publications

11.2K

Citations

H-Index

151

Concepts

All Affiliations

Peter MacCallum Cancer Centre The University of Melbourne The Royal Melbourne Hospital Monash University St Vincent's Hospital Melbourne

About

Simon J. Harrison is an author at Peter MacCallum Cancer Centre specializing in medicine, oncology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	42	2.5K
2	Health Sciences	14	16	729
3	Arts	1	1	20
4	Education	1	1	20
5	Engineering	1	1	64

Simon J. Harrison

135

Publications

8.2K

Citations

H-Index

Page 1

	Year	Citations
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study Michel Attal, Paul G. Richardson, S. Vincent Rajkumar, The Lancet Hematological MalignancyMedicineImmunologyHematologyPharmacotherapy	2019	620
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma Jesús F. San Miguel, Binod Dhakal, Kwee Yong, New England Journal of Medicine	2023	615
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial Shaji Kumar, Simon J. Harrison, Michèle Cavo, The Lancet Oncology Hematological MalignancyOncologyHematologyMyeloid NeoplasiaPharmacotherapy	2020	390
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM Philippe Moreau, Asher Chanan‐Khan, Andrew W. Roberts, Blood	2017	271
Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study Anas Younes, Anna Sureda, Dina Ben‐Yehuda, Journal of Clinical Oncology	2012	259
T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments Edwin D. Hawkins, Delfim Duarte, Olufolake Akinduro, Nature Hematological MalignancyMixed-phenotype Acute LeukemiaMalignant Blood DisorderImmunologyHematology	2016	199
First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study Amit Khot, Natalie Brajanovski, Donald P. Cameron, Cancer Discovery	2019	197
CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy Lauren Giuffrida, Kevin Sek, Melissa A. Henderson, Nature Communications	2021	194
FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy Jack D. Chan, C. Scheffler, Isabelle Munoz, Nature	2024	176
Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Suzanne Trudel, Adam D. Cohen, Amrita Krishnan, Blood	2021	158

Page 1